Ignite Creation Date:
2025-12-25 @ 4:03 AM
Ignite Modification Date:
2026-01-10 @ 12:51 PM
Study NCT ID:
NCT01434602
Status:
COMPLETED
Last Update Posted:
2022-06-01
First Post:
2011-09-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-10-02
Start Date Type:
ACTUAL
Primary Completion Date:
2020-10-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-07-13
Completion Date Type:
ACTUAL
First Submit Date:
2011-09-13
First Submit QC Date:
None
Study First Post Date:
2011-09-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-10-20
Results First Submit QC Date:
None
Results First Post Date:
2022-02-01
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-05-05
Last Update Post Date:
2022-06-01
Last Update Post Date Type:
ACTUAL